Acumen Pharmaceuticals (ABOS) Other financing activities (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Other financing activities of $145000.0 for Q1 2026, up 7150.0% sequentially from $2000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Other financing activities (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Other financing activities for 5 years, with the latest figure at $145000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $145000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184000.0 (changed N/A YoY) and the FY2025 annual result came in at $39000.0, changed N/A from the prior year.
- Other financing activities climbed to $145000.0 in Q1 2026 per ABOS's latest filing, from $2000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $325000.0 in Q3 2023 and troughed at -$19000.0 in Q4 2022.
- A 4-year average of $91857.1 and a median of $37000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2023: Other financing activities slumped 103.1% in 2022, then jumped 16150.0% in 2023.
- Over 4 years, Other financing activities stood at -$19000.0 in 2022, then surged by 894.74% to $151000.0 in 2023, then plunged by 98.68% to $2000.0 in 2025, then surged by 7150.0% to $145000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $145000.0, $2000.0, and $37000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -305,000.00 |
| Jun 30, 2026 | -305,000.00 |
| Mar 31, 2026 | 145,000.00 |
| Mar 31, 2026 | 145,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Sep 30, 2023 | 325,000.00 |
| Sep 30, 2023 | 325,000.00 |
| Dec 31, 2022 | -19,000.00 |
| Dec 31, 2022 | -19,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Dec 31, 2021 | 612,000.00 |
| Dec 31, 2021 | 612,000.00 |
| Sep 30, 2021 | -1.25 Mn |
| Sep 30, 2021 | -1.25 Mn |